论文部分内容阅读
本报告总结了在美国新奥尔良召开的第20届国际抗微生物制剂和化疗会议上发表的有关β-内酰胺酶抑制剂和抗真菌剂的新资料。其中有关Merck公司的硫霉素衍生物MK-0787的资料,已发表在Scrip 528期第13页。 Augmentin(羟氨苄青霉素+克拉维酸制剂)治疗组织感染的疗效来自英国和希腊的临床工作者在会上报告了他们利用Beecham公司的Augmentin(羟氨苄青霉素250毫克,克拉维酸125毫克)治疗由青霉素耐药菌引起的皮肤和软组织感染的临床试验结果。以前发表的临床试验结果主要是关于应用Augmentin治疗尿道和呼
This report summarizes new information on β-lactamase inhibitors and antifungals published at the 20th International Conference on Microbiological and Chemotherapy in New Orleans, USA. Among them, information on the Merck’s spiramycin derivative MK-0787 has been published in Scrip 528, p. 13. Therapeutic effect of Augmentin (amoxicillin + clavulanic acid preparation) for treatment of tissue infections Clinicians from the United Kingdom and Greece reported at the conference that they were using Augmentin (amoxicillin 250 mg, clavulanic acid 125 mg) from Beecham to treat Results of clinical trials of skin and soft tissue infections caused by penicillin-resistant bacteria. Previously published clinical trial results mainly focused on the use of Augmentin in the treatment of urinary tract and call